Yifan Pharmaceutical Hits Day Low of CNY 10.13 Amid Price Pressure

Yifan Pharmaceutical Co., Ltd. experienced a significant decline in its stock performance today, with a drop of 5.42%. The stock reached an intraday low of CNY 10.13, reflecting ongoing challenges within the company. Over the past year, Yifan has faced a notable decrease in profitability, with a net profit decline of 29.96% reported for the first half of the year. The company's financial metrics indicate a low return on capital employed (ROCE) of 2.72% and a return on equity (ROE) of 3.72%, suggesting limited profitability relative to its capital and shareholders' funds. Additionally, Yifan's net sales have contracted at an annual rate of 0.87% over the last five years, while operating profit has decreased by 10.49% during the same period. Despite being net-debt free, the company has struggled to maintain growth, with its stock generating a return of -28.92% over the past year. The current market capitalization stands at CNY 8,911 million, and the stock's price-to-earnings ratio is 34.00, indicating a relatively high valuation in the context of its financial performance.